1. Home
  2. XXII vs XRTX Comparison

XXII vs XRTX Comparison

Compare XXII & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

HOLD

Current Price

$4.05

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$0.40

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXII
XRTX
Founded
1998
2011
Country
United States
Canada
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
2.7M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
XXII
XRTX
Price
$4.05
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.5K
111.3K
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,832,530.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$79.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.67
$0.37
52 Week High
$11.37
$1.41

Technical Indicators

Market Signals
Indicator
XXII
XRTX
Relative Strength Index (RSI) 42.91 34.02
Support Level $1.68 $0.38
Resistance Level $6.86 $0.58
Average True Range (ATR) 0.66 0.03
MACD -0.35 0.00
Stochastic Oscillator 11.40 14.45

Price Performance

Historical Comparison
XXII
XRTX

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: